For Older AML Patients, Venetoclax With Low-Dose Cytarabine is Safe and “Promising”
3,195 views · Published 6 June 2016 · 4:49 · Indexed 19 October 2026
Channel: American Society of Hematology · 2016 · Nonprofits & Activism
Tara L. Lin, MD, shares the initial findings from a trial evaluating venetoclax with standard low-dose cytarabine in older patients with acute myeloid leukemia who are unfit for intensive chemotherapy.
More from this channel
-
1:52
Ron Reagan Accepts ASH Award - Stem Cell Research
-
4:25
Sen. Jim Talent's Work on Sickle Cell Disease Legislation
-
3:56
ASH and the Reagans Support Stem Cell Research
-
5:42
The American Society of Hematology Celebrates its 50th Anniversary
-
5:57
David Nathan Receives 2011 Wallace H. Coulter Award for Lifetime Achievement in Hematology
-
5:17
James George Receives 2012 Wallace H. Coulter Award for Lifetime Achievement in Hematology
-
2:21
Congress: Protect NIH funding
-
2:21
Act Now: Tell Congress to Stop Further Cuts to Research Funding